Contrast Enhanced Ultrasound for Evaluation of Reflux Nephropathy

Completed · Phase 2

Conditions studied: Urinary Tract Infection, Vesicoureteral Reflux

In brief

The study will be evaluating the efficacy and safety of a contrast drug in pediatric renal ultrasound.

Key facts

Study ID

NCT02786810

Run by

University of Tennessee

People needed

10

Starts

2016-03-01

Expected to finish

2016-11-01

Last updated by the study team

2018-05-11

Who can join

Age: 8 and older, up to 50. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Informed consent
• Age more than or equal to 8 years
• Patient with history of urinary tract infection (UTI) and history of Voiding Cystourethrogram (VCUG) for vesicoureteral reflux
• Candidate for Dimercaptosuccinic acid (DMSA) scan or scan for renal scar
• Demonstration of renal scarring by DMSA scan or renal ultrasound without contrast
• Includes healthy volunteers

You may not qualify if…

• Age less than 8years
• Allergy to contrast or related products
• Cardiac shunt/ congenital heart anomalies
• Abnormal baseline ECG
• Open heart surgery
• Evidence of retinopathy
• Patient in intensive care
• Unable to comply with study requirement
• History of emphysema
• Unable to maintain oxygen saturation of 92% on at room air
• Pregnancy and lactation

Where it is running

• University of Tennessee Health Science Center — Memphis, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.